Objective: To bring together state officials who are leading state innovation in prescription drug cost policy, and to connect them with the tools and resources they need to advance reforms.

Description: Open only to state officials, this half-day summit will provide a unique opportunity for state officials to examine what they can do to lower drug prices, the challenges these initiatives face and strategies to overcome them. The agenda is designed for and by states to help state legislators and staff, governors’ staff, state employee health benefit administrators, Medicaid, attorneys general and staff, and other state officials. During the day’s summit we will:

- Provide an overview of what states can and are doing to address the rising cost of prescription drugs
- Discuss the pharma industry’s approach and how to manage the lobbying and legal counter-efforts of this and other stakeholder groups

8:30-8:50 a.m.
Welcome and Overview
What have states been doing to lower drug costs in 2018?
What’s hot in state drug cost policy?
How has transparency legislation evolved over the course of the year?
How are states advancing wholesale importation programs from Canada?

Moderator: Trish Riley, NASHP

8:50-9:40 a.m.
Learning from Innovators: Transparency and Anti-Price-Gouging Laws
What can states learn from innovators’ experiences with first-in-nation transparency and anti-price-gouging laws?
What legal challenges have states faced? How can second-generation bills avoid legal challenges?
What would innovators do differently if they had the chance to do it again?
Could states work together to implement transparency?
What can transparency laws deliver?

Speakers:
- Joshua Wojcik: Policy Director, Office of the State Comptroller, Connecticut
- Julie Kotchevar: Deputy Director, Department of Health and Human Services, Nevada
- Jim Jones: Pharmaceutical Analytics and Technology Consultant, California
- Jane Horvath: Horvath Health Policy, Maryland

Moderator: David Seltz, Executive Director, Health Care Commission, Massachusetts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40-10:30 a.m.</td>
<td><strong>Beyond Transparency: Bold New Directions to Address Drug Costs</strong>&lt;br&gt;How can rate setting be applied to drug costs? How can a state tax manufacturers for price hikes? Can a state require drug advertisers to disclose a drug’s cost in ads to consumers? Can states consolidate forces working together as public purchasers? What other new policy options are available?&lt;br&gt;&lt;br&gt;<strong>Speakers</strong>&lt;br&gt;Virginia Lyons: State Senator, Vermont&lt;br&gt;Trevor Douglass: Oregon Prescription Drug Program &amp; Pharmacy Purchasing Director&lt;br&gt;Jane Horvath: Horvath Health Policy, Maryland&lt;br&gt;&lt;br&gt;<strong>Moderator:</strong> Norman Thurston, Utah State Representative</td>
</tr>
<tr>
<td>10:30-10:40 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>10:40-11:30 a.m.</td>
<td><strong>New Tools for Medicaid to Cut Drug Costs</strong>&lt;br&gt;How can Medicaid drug spending be limited? Can states adapt successful tactics from the commercial sector to control costs such as closed formularies?&lt;br&gt;&lt;br&gt;<strong>Speakers</strong>&lt;br&gt;Daniel Tsai: Medicaid Director, Massachusetts&lt;br&gt;Amir Bassiri: Department of Health, New York&lt;br&gt;Terry Cothran: Pharmacy Management Consultants, Oklahoma&lt;br&gt;&lt;br&gt;<strong>Moderator:</strong> Richard Gottfried, Chair, Committee on Health, New York State Assembly</td>
</tr>
<tr>
<td>11:30-11:50 a.m.</td>
<td><strong>State Strategy Discussion – State Drug Price Policy 2.0</strong>&lt;br&gt;What have we learned so far about what works – and what doesn’t work – to address drug prices? What hasn’t been tried that could be effective? How can a legislator manage the politics of drug cost initiatives? What drug cost issues have particular resonance with the public? How do you get the support (or eliminate objections) of system stakeholders other than pharma? What were pharma industry’s key tactics in fighting legislation? What measures does industry want to advance and why? Are there basic do’s and don’ts in moving drug cost/price legislation?&lt;br&gt;&lt;br&gt;<strong>Moderator Trish Riley,</strong> NASHP</td>
</tr>
<tr>
<td>11:50 a.m.-Noon</td>
<td><strong>Next Steps</strong>&lt;br&gt;What do states need to help advance this agenda? What can NASHP do to support state efforts?&lt;br&gt;&lt;br&gt;<strong>Moderator Trish Riley,</strong> NASHP</td>
</tr>
<tr>
<td>Noon</td>
<td><strong>Networking Lunch</strong>&lt;br&gt;Please join other summit attendees for an informal networking opportunity over lunch at the tables marked “Rx Summit Attendees.”</td>
</tr>
</tbody>
</table>